Surgery may not improve outcomes in early-stage prostate cancer
A 20-year study found that patients with early-stage prostate cancer who have surgery to remove their tumor do not live longer than those who receive no treatment.
A 20-year study found that patients with early-stage prostate cancer who have surgery to remove their tumor do not live longer than those who receive no treatment.
The USPSTF recommends that prostate cancer screenings should be an individual decision.
Antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long-term overall survival.
Cases of prostate biopsies resulting in the spread of cancerous cells are rare.
Vasectomy can continue to be a safe method of contraception in men.
A recent cohort study evaluated the risk of developing Alzheimer dementia after ADT in 16,888 men with prostate cancer, 14.2% of whom were treated with ADT.
The analysis of diagnostic characteristics may predict the result of a confirmatory biopsy.
Patients treated with androgen deprivation therapy had a 1.88-times increased rate of developing Alzheimer’s disease.
New research suggests that men with low-risk prostate cancer who undergo choose watchful waiting may not receive timely treatment when compared to those undergoing active treatment.
In the United States, the rate of prostate cancer screening is down, and the number of men diagnosed with the disease has also dropped.